Drug Trial Radar · NCT04573478
Atrasentan in Patients With IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
404
Actual
Start
Dec 11, 2020
Primary completion
Apr 14, 2028
Study completion Apr 14, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
Conditions
- IgA Nephropathy
- Immunoglobulin A Nephropathy
Interventions
AtrasentanDrug
Film-coated tablet
PlaceboDrug
Film-coated tablet
ZigakibartDrug
pre-filled syringes with needle safety device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind period: Change in proteinuriaTime frame: Up to Week 36 or approximately 9 months
- Open-label period: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)Time frame: From open-label baseline up to end of treatment visit, up to 48 weeks
- Open-label period: Number of Subjects With Adverse Events of Special Interest (AESI) Including Events of Fluid OverloadTime frame: From open-label baseline up to end of treatment visit, up to 48 weeks
- Substudy period: Number of subjects with TEAEsTime frame: From substudy baseline to end of treatment, up to 48 weeks
- Substudy period: Number of subjects with AESITime frame: From substudy baseline to end of treatment, up to 48 weeks
Locations
135 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Comprehensive Research Institute
Alhambra, California
Kidney Disease Medical Group
Glendale, California
Stanford University
Stanford, California
University of Florida
Gainesville, Florida
GA Nephrology Associates
Lawrenceville, Georgia
NANI Research, LLC
Hinsdale, Illinois
NANI Research, LLC
Fort Wayne, Indiana
University of Louisville Physicians- Kidney Disease Program
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
Intermed Consultants
Minneapolis, Minnesota
Pelican Point Dialysis - DaVita Clinical Research
Las Vegas, Nevada
Capital District Renal Physicians
Clifton Park, New York
Mountain Kidney and Hypertension Associates
Asheville, North Carolina
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina
Lehigh Valley Hospital
Bethlehem, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Liberty Research Center
Dallas, Texas
El Paso Kidney Specialists
El Paso, Texas
Nephrology Associates Of Northern Virginia
Fairfax, Virginia
Swedish Health Services
Seattle, Washington
CEMIC
Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Buenos Aires, Argentina
Clinica de Nefrologia Urologia y Enf. Cardiovasculares
Santa Fe, Argentina
Centro Médico Ce.Re.Ca
San Luis, San Luis Province, Argentina
Box Hill Hospital
Box Hill, Australia
Royal Brisbane & Women's Hospital
Brisbane, Australia
Monash Medical Centre
Clayton, Australia
Renal Research
Gosford, Australia
Nepean Hospital
Kingswood, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Melbourne Renal Research Group
Reservoir, Victoria, Australia
Sunshine Hospital
Saint Albans, Victoria, Australia
Hospital das Clínicas Universidade Federal de Minas Gerais - UFMG
Belo Horizonte, Brazil
Centro de Pesquisa Clinica do Brasil
Brasília, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil
Praxis Pesquisa Médica
Santo André, Brazil
Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, Brazil
Hospital do Rim Fundacao Oswaldo Ramos
São Paulo, Brazil
Instituto Pró-Renal Brasil
Curitiba, Paraná, Brazil
Showing 40 of 135 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.